A randomised clinical trial of treatment for fluorouracil-resistant advanced colorectal cancer comparing standard single-agent irinotecan versus irinotecan plus panitumumab and versus irinotecan plus ciclosporin

Trial Profile

A randomised clinical trial of treatment for fluorouracil-resistant advanced colorectal cancer comparing standard single-agent irinotecan versus irinotecan plus panitumumab and versus irinotecan plus ciclosporin

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Ciclosporin (Primary) ; Irinotecan (Primary) ; Panitumumab (Primary)
  • Indications Colorectal cancer
  • Focus Biomarker; Registrational; Therapeutic Use
  • Acronyms PICCOLO
  • Most Recent Events

    • 02 Sep 2015 Accrual to date is 73 % as per United Kingdom Clinical Research Network record.
    • 02 Jun 2015 Effects of miR 31 3p expression on response presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 01 Jun 2015 According to an IntegraGen media release, data from this study were presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top